Early Phase 1 N=72 Developing a Mobile Method to Measure THC-induced Impairment
Measuring THC-induced Cognitive Impairment Using a Mobile Application
Primary: Simple Reaction Time — .365; .386; .396 Seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=45 Transcranial Magnetic Stimulation (TMS) for Motor Symptoms in Psychiatric Disorders
Psychomotor Retardation · Psychomotor Slowing · Schizophrenia and Related Disorders
Primary: Number of Responders at Week 3 — 4; 9; 0; 3 responders
Phase 1 N=12 Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function
Renal Impairment · Tuberculosis
Primary: Fold Change in Pretomanid AUC(0-last) in Participants With Renal Impairment as Compared to Matched Healthy Controls — 77130; 63600; 62660 ng*h/mL
Phase 1 N=16 Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function
Infections, Bacterial
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinity (AUC[0-inf]) for Plasma Gepotidacin — 15894.7; 19505.7; 25415.5…
Phase 1 N=16 Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function
Migraine
Primary: Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) — 259; 293 nanogram per milliliter (ng/mL)
N/A N=300 SAGE for the Early Detection of Cognitive Impairment at Primary Care Provider Visits
Cognitive Impairment
Primary: Number of Participants With a Diagnosis of a Cognitive Impairment Disorder Measured by Pharmacological Interventions for the Management of Cognitive Impairment. — 0; 0…
N/A N=7 The Use of Psychomotor Vigilance Testing in the Assessment of Pediatric Obstructive Sleep Apnea
Pediatric Obstructive Sleep Apnea
Primary: Number of Participants Who Achieved Criteria of Obstructive Sleep Apnea in the PVT Assessment — 5; 2 Participants
Phase 1 N=23 Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment
Renal Impairment
Primary: Dose-Normalized Maximum Concentration of Plerixafor (Cmax) — 0.0452; 0.0388; 0.0490; 0.0475 ng/mL/ug
Phase 1 N=24 Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function
Infections, Bacterial
Primary: Area Under the Plasma Concentration Time Curve (AUC) From Hour 0 to Infinity (AUC[0-inf]) of Gepotidacin for Part 1 — 14838; 22367; 28545 Nanogram*hour per milliliter
N/A N=16 Improving Physical Activity With Cognitive Impairment
Mild Cognitive Impairment · Caregiver Burnout
Primary: TPAB Intervention Participant Retention — 5; 5; 3; 3 Participants
N/A N=39 Exercise Training and Cognitive Function in Kidney Disease
Cognitive Function, Preclinical · Chronic Kidney Diseases · Older Adults
Primary: Composite Global Cognitive Function — .15; .02 Z-score
Phase 1 N=27 Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.
Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-07321332 — 1600; 2077; 2210; 2369 Nanogram per milliliter
N/A N=167 Fosamprenavir in Pts With Hepatic Impairment
Infection, Human Immunodeficiency Virus
Primary: Number of Events of ALT Elevation After Baseline, Controlling for APRI Score and Other Variables — 9; 4 events — p=0.02
N/A N=170 Asymptomatic Carotid Stenosis: Cognitive Function and Plaque Correlates
Cognitive Manifestations
Primary: Composite Cognitive Score — 45.5; 47.9 units on a scale
Phase 1 N=16 A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)
Renal Impairment
Primary: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of N-hydroxycytidine (NHC) — 11100; 8960 hr*ng/mL